Developing new antibodies to prevent HIV infection
Official title: Next Generation Development of Broadly Neutralizing HIV Antibodies for Prevention
Funded at Advanced Bioscience Laboratories, INC. · NIH-11041822 · Data updated 2026-11-12
This study is looking at new types of antibodies that can help fight HIV, with the goal of making treatments and prevention methods better for people living with or at risk of HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advanced Bioscience Laboratories, INC. NIH-funded |
| Lab location | 1 site (Kensington, United States) |
| Project start | September 9, 2018 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $326,373 |
| NIH project number | 272201700010I-P00009-27200009-1 |
| Project ID | NIH-11041822 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk of HIV infection or those currently living with HIV who may benefit from enhanced treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who are already receiving effective treatment may not receive direct benefits from this research.
What this research studies
This research focuses on creating broadly neutralizing antibodies (bnAbs) that can effectively target and neutralize the HIV virus. By evaluating multiple bnAbs that recognize different parts of the HIV envelope, the research aims to improve treatment and prevention strategies for HIV. The approach includes testing antibodies like VRC01, PGDM1400, and PGT121, and exploring modifications to enhance their effectiveness and longevity in the body. Patients may benefit from these advancements in HIV prevention and treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV prevention methods and improved treatment options for patients living with HIV.
How similar studies have gone: Previous research has shown promise in using broadly neutralizing antibodies for HIV treatment and prevention, indicating a potential for success in this novel approach.
Where this research is happening
-
Advanced Bioscience Laboratories, INC.
Kensington, United States Active
Researchers
- Principal investigator: Fouts, Timothy — Advanced Bioscience Laboratories, INC.
- Study coordinator: Fouts, Timothy
Related research
Other NIH-funded projects on the same topics.
-
Development of vaccines and biologics for infectious diseases
This study is working on creating new vaccines to help protect people from infectious diseases, and it aims to make sure these vaccines are safe and effective before they are approved for use.
-
Developing new vaccines and biologics for infectious diseases
This study is all about creating and improving vaccines to help protect people from tough infections, including those that are hard to treat and could be used in bioterrorism, so that patients can have better options for staying healthy.
-
Developing a vaccine to fight fungal infections
This study is working on a new vaccine to help protect people, especially those with weakened immune systems, from serious fungal infections like Candida auris and Cryptococcus neoformans, which can be tough to treat.
-
Identifying and testing a new antibody treatment for Duchenne Muscular Dystrophy.
This study is looking at a new treatment for Duchenne Muscular Dystrophy (DMD) using a special type of antibody, and it aims to make sure the drug is safe and works well before it can be tested in people like you.
-
Developing and testing new oligonucleotides for medical use
This study is working on creating new types of medicines that target specific genes, which could lead to better treatments for patients with various health conditions.
-
Manufacturing a new treatment for pain management
This study is exploring a new way to help manage pain using a special compound called VHCA8*, and it's designed for people looking for better pain relief options that are safe and backed by science.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.